Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Healthcare Sector Analysis

UpdatedApr 21, 2026
DataAggregated Company Financials
Companies146
  • 7D4.3%
  • 3M6.6%
  • 1Y10.9%
  • YTD4.8%

In the last week, the Healthcare industry is up 5.1%, with Swedish Orphan Biovitrum leading the way, up 3.7%. This takes the industry's 12 month performance to a gain of 12%. As for the next few years, earnings are expected to grow by 25% per annum.

Sector Valuation and Performance

Has the Swedish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 21 Apr 2026SEK 612.0bSEK 228.2b-SEK 2,632,658,442.2234.4x-232.5x2.7x
Thu, 19 Mar 2026SEK 550.2bSEK 228.8b-SEK 2,896,686,591.9730.7x-189.9x2.4x
Sat, 14 Feb 2026SEK 565.4bSEK 230.9b-SEK 1,751,199,327.3530.8x-322.8x2.4x
Mon, 12 Jan 2026SEK 599.8bSEK 230.2bSEK 3.7b41x163.5x2.6x
Wed, 10 Dec 2025SEK 582.0bSEK 230.6bSEK 3.5b41.2x164.2x2.5x
Fri, 07 Nov 2025SEK 588.5bSEK 229.2bSEK 2.8b45.4x212.8x2.6x
Sun, 05 Oct 2025SEK 614.1bSEK 227.1bSEK 6.6b43.2x93x2.7x
Tue, 02 Sep 2025SEK 623.8bSEK 227.1bSEK 6.6b46.1x94.7x2.7x
Thu, 31 Jul 2025SEK 632.0bSEK 226.9bSEK 6.5b54.1x96.6x2.8x
Sat, 28 Jun 2025SEK 616.8bSEK 226.8bSEK 5.9b44.9x105.1x2.7x
Mon, 26 May 2025SEK 587.3bSEK 226.0bSEK 6.6b37x89.3x2.6x
Wed, 23 Apr 2025SEK 549.9bSEK 222.1bSEK 5.0b37.5x110.7x2.5x
Fri, 21 Mar 2025SEK 558.9bSEK 206.3bSEK 5.0b37x112x2.7x
Sun, 16 Feb 2025SEK 594.9bSEK 206.4bSEK 2.5b41.7x236.5x2.9x
Tue, 14 Jan 2025SEK 571.2bSEK 201.6b-SEK 2,648,325,362.5039.2x-215.7x2.8x
Thu, 12 Dec 2024SEK 575.6bSEK 202.8b-SEK 2,465,020,947.5338.6x-233.5x2.8x
Sat, 09 Nov 2024SEK 528.5bSEK 200.2b-SEK 2,597,706,631.9538.6x-203.4x2.6x
Mon, 07 Oct 2024SEK 607.5bSEK 200.2b-SEK 2,782,910,611.7639.8x-218.3x3x
Wed, 04 Sep 2024SEK 607.0bSEK 200.0b-SEK 2,809,391,402.8740x-216.1x3x
Fri, 02 Aug 2024SEK 584.7bSEK 199.7b-SEK 2,762,785,972.7841.1x-211.6x2.9x
Sun, 30 Jun 2024SEK 562.0bSEK 195.7b-SEK 3,202,643,667.9236.8x-175.5x2.9x
Tue, 28 May 2024SEK 552.0bSEK 196.0b-SEK 2,798,220,083.8936.2x-197.3x2.8x
Thu, 25 Apr 2024SEK 521.0bSEK 194.1b-SEK 3,331,281,004.7543.9x-156.4x2.7x
Sat, 23 Mar 2024SEK 519.8bSEK 192.7b-SEK 3,669,066,937.9843.3x-141.7x2.7x
Mon, 19 Feb 2024SEK 516.9bSEK 191.7b-SEK 4,080,444,504.7249.9x-126.7x2.7x
Wed, 17 Jan 2024SEK 551.4bSEK 191.7b-SEK 967,683,823.0048.2x-569.8x2.9x
Fri, 15 Dec 2023SEK 517.8bSEK 191.2b-SEK 999,563,618.0048.9x-518x2.7x
Sun, 12 Nov 2023SEK 470.7bSEK 190.4b-SEK 1,080,492,686.0049.4x-435.7x2.5x
Tue, 10 Oct 2023SEK 439.1bSEK 185.1b-SEK 2,032,014,505.0033.8x-216.1x2.4x
Thu, 07 Sep 2023SEK 457.1bSEK 185.8b-SEK 2,013,608,879.0035.8x-227x2.5x
Sat, 05 Aug 2023SEK 473.1bSEK 183.9b-SEK 1,003,843,769.0039.9x-471.3x2.6x
Mon, 03 Jul 2023SEK 480.3bSEK 179.2b-SEK 793,306,793.0044.7x-605.5x2.7x
Wed, 31 May 2023SEK 504.9bSEK 178.9b-SEK 549,905,700.0043.5x-918.2x2.8x
Fri, 28 Apr 2023SEK 513.3bSEK 174.8b-SEK 1,487,139,903.0035.1x-345.1x2.9x
Price to Earnings Ratio

-345.1x


Total Market Cap: SEK 513.3bTotal Earnings: -SEK 1,487,139,903.00Total Revenue: SEK 174.8bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Healthcare Sector Price to Earnings3Y Average -161.2x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swedish Healthcare industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 2.7x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have deteriorated over the last three years.
  • Meanwhile revenues for these companies have grown 9.7% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare sector?

SE Market2.74%
Healthcare4.32%
Healthtech10.21%
Pharma6.90%
Life Sciences5.62%
Healthcare Services3.80%
Biotech3.35%
Medical Equipment2.80%
Industry PE
  • Investors are most optimistic about the Healthtech industry which is trading above its 3-year average PE ratio of 117x.
    • Analysts are expecting annual earnings growth of 20.0%, which is higher than its past year's earnings growth of 1.5% per year.
Forecasted Growth
  • Analysts are most optimistic on the Pharma industry, expecting annual earnings growth of 35% over the next 5 years.
  • This is better than its past earnings growth rate of 14% per year.
  • In contrast, the Life Sciences industry is expected to see its earnings grow by 19% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SECT B SectraSEK 265.0010.5%
+SEK 4.9b		-3.6%PE95x
SOBI Swedish Orphan BiovitrumSEK 418.003.0%
+SEK 4.1b		58.9%PE302.3x
CAMX CamurusSEK 564.009.5%
+SEK 2.9b		-0.4%PE45.8x
ASKER Asker Healthcare GroupSEK 79.3010.0%
+SEK 2.8b		4.2%PE57.4x
GETI B GetingeSEK 200.904.7%
+SEK 2.4b		3.5%PE24.2x

Latest News

BONEX
SEK 263.60
Bonesupport Holding
7D
11.7%
1Y
-14.8%
SECT B
SEK 265.00
Sectra
7D
10.5%
1Y
-3.6%
VIMIAN
SEK 30.10
Vimian Group
7D
-2.1%
1Y
-19.8%

VIMIAN: Higher Discount Rate Will Constrain Future Upside Potential

Analysts have trimmed their price target on Vimian Group to SEK 25 from SEK 27, reflecting updated views on discount rates, growth and profitability assumptions. Analyst Commentary Bearish analysts are signaling a more cautious stance on Vimian Group, with the latest move being a reduction in the price target to SEK 25 from SEK 27.
EGTX
SEK 5.36
Egetis Therapeutics
7D
-8.5%
1Y
58.8%
GETI B
SEK 200.90
Getinge
7D
4.7%
1Y
3.5%
CAMX
SEK 564.00
Camurus
7D
9.5%
1Y
-0.4%

CAMX: 2026 Earnings Guidance Will Support Further Share Price Upside

Analysts have maintained their SEK 930 price target on Camurus, supported by updated forecasts that reflect slightly higher revenue growth, a marginally stronger profit margin, and a modestly lower future P/E assumption. What's in the News Camurus issued earnings guidance for 2026, with expected revenues in a range of SEK 2.6b to SEK 2.9b.
AMBEA
SEK 135.30
Ambea
7D
-2.3%
1Y
22.6%

AMBEA: Danish Expansion And Higher Dividend Will Support Future Upside

Analysts have maintained their SEK158.33 price target for Ambea, making only minor adjustments to the discount rate, revenue growth, profit margin and future P/E, which supports a steady view on the shares. What's in the News Ambea is expanding in Denmark through Altiden, which has agreed to operate a new 96 resident care home in Munkebo, Kerteminde Municipality.
VITR
SEK 111.00
Vitrolife
7D
11.8%
1Y
-28.2%

VITR: Governance Amendments And Steady Assumptions Will Support Future Upside

Analysts have reduced their price target for Vitrolife to SEK 163.40 from SEK 176.75, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E. What's in the News Vitrolife AB (publ) has proposed amendments to its Articles of Association to be decided at the Annual General Meeting scheduled for May 5, 2026.
SOBI
SEK 418.00
Swedish Orphan Biovitrum
7D
3.0%
1Y
58.9%
ALIF B
SEK 165.00
AddLife
7D
5.5%
1Y
7.1%

ALIF B: Higher Margins And Dividend Outlook Will Support Future Upside

Analysts have maintained their SEK 187.50 price target on AddLife, with updated assumptions around discount rate, revenue growth, profit margin and future P/E that now reflect a slightly different balance of risk, earnings potential and valuation multiples. What's in the News AddLife AB (publ) announced an annual dividend of SEK 1.50 per share, with ex date on May 7, 2026, record date on May 8, 2026, and payment on May 13, 2026 (Key Developments).
BIOA B
SEK 329.60
BioArctic
7D
-0.9%
1Y
96.1%

BIOA B: NLRP3 Opportunity And Alzheimer’s Data Will Shape Balanced Outlook

The analyst fair value estimate for BioArctic has shifted from SEK 294.60 to SEK 303.80, with analysts pointing to more constructive views on the NLRP3 opportunity set and comparisons to bullish Street research on peers as key drivers behind the updated target assumptions. Analyst Commentary Bullish analysts are drawing parallels between BioArctic's NLRP3 exposure and Street enthusiasm around peers such as BioAge Labs, where recent research has highlighted NLRP3 programs and adjacent cardiovascular and ophthalmology opportunities as a key value driver.
STIL
SEK 213.50
Stille
7D
-4.3%
1Y
2.2%
CRNO B
SEK 6.01
Cereno Scientific
7D
-4.3%
1Y
-21.1%
ASKER
SEK 79.30
Asker Healthcare Group
7D
10.0%
1Y
4.2%
MVIR
SEK 1.90
Medivir
7D
-22.0%
1Y
9.6%

Rare Disease And Liver Cancer Pipeline Will Transform Long Term Prospects

Catalysts About Medivir Medivir is a biotech company focused on developing first in class therapies in oncology and rare bone diseases, alongside partnered programs in animal health. What are the underlying business or industry changes driving this perspective?
IMP A SDB
SEK 44.45
Implantica
7D
-8.6%
1Y
71.0%